Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07271030

The Use of Cannabidiol Suppositories for Sexual Pain

Research aim: To determine how cannabidiol suppositories might reduce sexual pain during intimacy. Outcomes are also hoped to increase sexual functioning, well-being, and quality of life.

Research intention: If cannabidiol suppository intervention reduces sexual pain and increases general well-being, then this research would be repeated on a larger scale, targeting psychosexual services.

A brief overview of the intervention:

Quantitatively, randomisation of cannabidiol suppositories will be into dose-specific groups. The intervention will be delivered over a period of one month, with follow-up scheduled at 12 weeks. Qualitatively, participants were asked approximately eight open-ended feedback questions throughout the study.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Well-Being, Psychological Behavior Personal Satisfaction Psychological Well-Being Quality of Life Sexual Behavior Sexual Pain Disorder

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

School of Social Sciences and Professions

London, N7 8DB, United Kingdom

Location status: Recruiting

Location contact

Samantha Banbury, PhD

CONTACT

[email protected]

About this study

Sexual pain is a constellation of biopsychosocial disorders which affects men, women and their partners.

Cannabidiol is one of approximately 100 cannabinoids found in cannabis, alongside tetrahydrocannabinol. Cannabidiol is non-intoxicating and regarded as a safe product to use. Cannabidiol has many applications, including in sexual health. Two studies have examined cannabidiol suppositories for supporting sexual function and reducing sexual pain. In both studies, outcomes suggested the pain relieving qualities of cannabidiol oil for both men and women.

This research aims to establish the effectiveness of varied doses of cannabidiol oil to minimise sexual pain and increase well-being. This research is a preliminary study looking at how cannabidiol suppositories aim to reduce pain and support sexual function, wellbeing and quality of life among those experiencing sexual discomfort or pain during intercourse or masturbation.

There will be four groups, where cannabidiol will be randomised to dose-specific groups, approximately 30, 50, and 100mg, under the guidance of a medical practitioner. There will also be a care as usual group.

It is hypothesised that:

Higher levels of sexual functioning, quality of life and wellbeing with lower levels of sexual pain will be reported among those using cannabidiol suppositories at the follow-up after intervention compared to care as usual group.

It is further hypothesised that higher doses of cannabidiol suppositories will have higher levels of sexual pain-reducing outcomes.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has previously used cannabidiol in any capacity and has not experienced any allergic reaction
  • Is experiencing sexual pain
  • There will be an absence of co occurring difficulties
  • Has attempted sexual intercourse in the last month
  • Age 18 years or older
  • Read and write English
  • Patient Health Questionnaire 9 screening score range between 0-9 mild
  • General Anxiety Disorder 7 screening score range between 0-9 mild
  • There are no restrictions on sex, gender, sexuality, or disability

Exclusion criteria

Has experienced an allergic reaction to cannabidiol in any capacity

  • Has not attempted sexual intercourse in the last month
  • Has co occurring difficulties
  • Aged below 18 years old
  • Are not experiencing sexual pain
  • Patient Health Questionnaire 9 screening score range between moderate to severe - 10-27
  • General Anxiety Disorder 7 screening score range between 10- 21.

Treatment and study plan

Cannabidiol suppository intervention 1

Dietary Supplement

Cannabidiol suppository dose specific 30mg

Cannabidiol suppository intervention 2

Dietary Supplement

Cannabidiol suppository dose specific 50mg

Cannabidiol suppository intervention 3

Dietary Supplement

Cannabidiol suppository dose specific 100mg

Non cannabidiol group control

Other

Care as usual group

Primary outcomes

  1. The Female Sexual Function Index

    Time frame: 0, 4 and 12 weeks

    This is a 19 item measure of sexual pain, sexual desire, orgasm, lubrication, and sexual satisfaction with five response categories. The score range is 2.0 to 36.0 with 26.0 being the cut of for sexual dysfunction. Example questions include, Over the past 4 weeks, how often did you experience discomfort or pain during vaginal penetration? and Over the past 4 weeks, how would you rate your level of discomfort or pain during or following vaginal penetration? Cronbach alpha for this questionnaire is .820 and higher.

  2. The Short Warwick Edinburgh Mental Well-being Scale

    Time frame: 0, 4 and 12 weeks

    This is a 7 item questionnaire with 5 response categories looking at functioning and feeling aspects of well-being. The response categories include 1=none of the time to 5=all of the time. Cronbach alpha for the questionnaire is 0.89-0.91. There is no reverse scoring. Scores range from 7 to 35 where the latter is the highest level of wellbeing.

  3. Brief Quality of Life Scale

    Time frame: Weeks 0, 4 and 12

    An 8 item questionnaire with five response categories looking at satisfaction with self, friends, family and creativity. This scale is scored by transforming the individual item scores from a 1 to 5 scale to a 0 to 100 scale. Example responses include how I view my life as necessary for my quality of life, and I am satisfied with my friends and friendship: The Cronbach alpha is .760 for this questionnaire

  4. Changes in levels of anal pain taken

    Time frame: Weeks 0, 4 and 12

    The frequency and severity of pain during anal sex, this is a 5-point Likert-type scale which ranges from never (5) to all the time (1) and no anal pain (5) to severe anal pain (1). The Cronbach alpha in this study= 0.70.

Study contacts

Contact information is provided by the study sponsor or research team.

Anna Kamyk

CONTACT

[email protected]

02074230000

Sponsors and collaborators

Lead sponsor

London Metropolitan University

Other

Registry information

Official study title

The Use of Cannabidiol Suppositories for Sexual Pain: A Randomised Controlled Study

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Dec 8, 2025
Registry last updated
Jan 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.